Buy & Sell Bristol-Myers Squibb Co (BMY) – Bristol-Myers Squibb Co Price Today
Aura AI Summary
Key Stats
- $116.40BMarket Cap
- HealthSector
- -10.74%3M Drawdown
- $152.34BEnterprise Value
- 4.42%Dividend Yield
- 71% Buy | 29% SellTrading Activity
- 92 daysTypical Hold Time
Bristol-Myers Squibb Co (BMY) is currently valued at a market capitalization of $116.40B, with an enterprise value of $152.34B. Over the past 52 weeks, Bristol-Myers Squibb Co has traded between a low of $42.6 and a high of $62.37, highlighting its annual price range. Over the past three months, Bristol-Myers Squibb Co has recorded a drawdown of -10.74%, reflecting recent price volatility. Bristol-Myers Squibb Co offers a dividend yield of 4.42%, with the most recent dividend of $0.63 paid on 02 Apr 26. On average, investors hold Bristol-Myers Squibb Co for approximately 92 days, indicating typical investor behavior on the platform.
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Small-cap ETFs may rebound as investors overlook them amid mega-cap tech focus, creating potential buying opportunities.
Small-cap stocks are starting to outperform again, but ETF investors remain focused on mega-cap technology and AI stocks, leading to small-cap ETFs holding only about 4% of ETF assets down from 10%. Despite $25 billion outflows from small-cap mutual ...